Instalab
logoInstalab

Syphilis Antibody Cascading Reflex

Blood Test
See not just whether you have syphilis, but whether it is active and needs treating today, all from one blood draw.
4.9 (4,398 reviews)
Tested by Quest Diagnostics
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home or at 2,000+ patient service centers
Get results
Explained with clear next steps, no medical jargon

Should you take a Syphilis Antibody Cascading Reflex test?

This test is most useful if any of these apply to you.

Sexually Active With New Partners
With new or multiple partners, this panel shows whether syphilis is active now, not just whether you were once exposed.
Living With HIV or Taking PrEP
Because syphilis often occurs alongside other sexually transmitted infections, frequent screening catches new cases early.
Planning or Expecting a Pregnancy
Untreated syphilis can pass to your baby, so confirming your status early protects both of you.
Treated Before and Tracking Recovery
After treatment, repeat testing confirms the infection is clearing or flags a reinfection before it spreads.

About Syphilis Antibody Cascading Reflex

Syphilis is climbing again after decades of decline, and it is easy to miss because it often causes no symptoms for months or years. A single antibody test can tell you that your body has met the bacteria, but it cannot tell you whether you have an infection that needs treatment now.

This panel solves that problem by running as a cascade. It begins with a sensitive antibody screen, then adds two measurements that separate an active infection from one that is old, already treated, or a false alarm.

What This Panel Reveals

The first test, called a treponemal test because it targets the bacterium itself, looks for antibodies aimed specifically at the syphilis bacterium (called T. pallidum). These antibodies are the most sensitive early signal of infection, and they usually stay in your blood for life, even after successful treatment. That permanence is useful for detection but creates a problem: a positive result alone cannot tell an active infection from one you cleared years ago.

The rapid plasma reagin tests, known as RPR, supply the missing information. These are non-treponemal tests: rather than targeting the bacterium directly, RPR detects antibodies your body makes against fatty molecules released when active syphilis damages tissue, so it tends to track whether the disease is currently doing harm. Because those same antibodies can appear in other conditions, RPR is read alongside the treponemal test rather than on its own. The RPR titer puts a number on that activity by measuring how much of this antibody is present, which is what lets the panel stage the infection and follow it over time.

How to Read Your Results Together

Reading the three results as a set is where the panel earns its value. The antibody test tells you whether syphilis is on the table at all, and the RPR results tell you what to do about it.

PatternWhat It Likely Means
Antibody reactive / RPR reactiveLikely active syphilis. The titer stages it and becomes your baseline for tracking treatment.
Antibody reactive / RPR nonreactiveOften past treated or long-standing latent infection, sometimes a very early primary infection or a false-positive screen. A second treponemal test and your history sort these apart.
Antibody nonreactive / RPR reactiveUsually a biological false positive rather than syphilis.
Antibody nonreactive / RPR nonreactiveNo serologic evidence of syphilis, though a very recent infection can still be too new to show.

That second pattern is common and worth understanding. In one large analysis, 58% of positive antibody screens had a nonreactive RPR, and 72% of those reflected real prior infection rather than a testing error. A nonreactive RPR does not simply cancel out a positive antibody result.

What to Do with Your Results

Any reactive result deserves prompt clinical follow-up, because syphilis is curable with antibiotics and the cost of missing it is high. If both the antibody test and RPR are reactive, expect a clinician to confirm staging, treat, and use your RPR titer as the baseline. A fourfold rise in titer later points to new infection or reinfection, while a fourfold fall after treatment signals the infection is clearing.

If your antibody test is reactive but RPR is not, a second, different treponemal test helps distinguish genuine past infection from a false-positive screen. Because syphilis and the virus that causes AIDS (HIV) often travel together, a reactive result is also a reason to test for HIV and other sexually transmitted infections. In pregnancy the stakes are highest: programs that screen and treat pregnant people have been associated with a 93% reduction in congenital syphilis cases, based mainly on point-of-care testing in low-resource settings compared with standard laboratory screening.

When Results Can Be Misleading

A few panel-wide traps are worth knowing. Very early infection can trip the antibody test before RPR becomes reactive, so a fresh exposure may show only a positive antibody. At the opposite extreme, extremely high antibody levels can overwhelm the RPR reaction and produce a falsely nonreactive result (called the prozone effect), though this happens in under 0.85% of samples.

Conditions such as lupus, pregnancy, and some infections can also make RPR reactive without syphilis, which is exactly why the treponemal test anchors the diagnosis. And some people stay serofast, keeping a low RPR that never fully clears despite a cure, so titers are read as a trend rather than a single verdict.

Frequently Asked Questions

References

10 studies
  1. Seungjun Lee, Hui-jin Yu, Sangeun Lim, Hyosoon Park, Min-jung Kwon, H. WooInternational Journal of Infectious Diseases2019
  2. M. Morshed, Min-kuang Lee, Jonathan Laley, D. Cook, Annie Mak, Navdeep Chahil, M. KrajdenMicrobiology Spectrum2022
  3. Ina U. Park, J. Chow, G. Bolan, M. Stanley, Jennifer Shieh, J. SchapiroThe Journal of Infectious Diseases2011
  4. Daniel a. Ortiz, Mayur R. Shukla, M. LoeffelholzClinical Infectious Diseases2020